Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Telik has commenced a multicenter Phase 2 clinical trial to investigate Telintra in patients who are suffering from Revlimid refractory or resistant, deletion 5q myelodysplastic syndrome (del 5q MDS).
Subscribe to our email newsletter
The company plans to recruit around 117 patients in the trial.
The primary objective of the trial is to establish the hematologic improvement-erythroid (HI-E) response rate as measured by transfusion reduction or independence, in accordance with the International Working Group MDS 2006 criteria.
However, the secondary objectives include determination of the hematologic improvement-neutrophil (HI-N) and hematologic improvement-platelet (HI-P) response rates, and safety.